Drug intelligence / Profile preview

diphenhydramine + guaifenesin + levomenthol

Development stage
Unknown
Lead developer
Gaco Pharmaceuticals
Modality
Small Molecules
Administration
Oral
01

Overview

Antuss Plus is an oral combination medication developed by Gaco Pharmaceuticals, designed for the symptomatic relief of coughs and congestion associated with the common cold and respiratory infections. The formulation contains three active ingredients: diphenhydramine hydrochloride, guaifenesin, and levomenthol. Diphenhydramine is a first-generation antihistamine that acts as an H1-receptor antagonist, providing antitussive effects by reducing the cough reflex and alleviating allergic symptoms. Guaifenesin is an expectorant that works by increasing the volume and reducing the viscosity of respiratory tract secretions, thereby facilitating the clearance of mucus from the airways. Levomenthol provides a cooling sensation and mild local anesthetic effect on the throat and nasal passages by acting as a TRPM8 agonist. Together, these components address both productive and non-productive coughs while soothing irritated respiratory tissues.

Brand names
Antuss Plus
Other names
Antuss Plus-Gaco Pharmaceuticals-oralDiphenhydramine / Guaifenesin / Levomenthol
02

Targets

HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on diphenhydramine + guaifenesin + levomenthol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on diphenhydramine + guaifenesin + levomenthol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call